Novel carrier-free nanoparticles enhance diabetic wound healing by simultaneously fighting infection and inflammation.
Diabetic wound ulcers, characterized by chronic infection and persistent inflammation, significantly impair patient quality of life and present substantial socioeconomic burdens. Traditional therapeutic strategies frequently encounter challenges, including antibiotic resistance, systemic side effects, and inadequate control over localized inflammation. We herein developed novel carrier‐free nanoparticles (CeCur NPs) by self‐assembling chlorin e6 (Ce6) and curcumin, achieving simultaneous photodynamic antibacterial activity and sustained anti‐inflammatory effects. CeCur NPs exhibited effective and synergetic anti‐bacteria and anti‐inflammation both in vitro and in vivo. Comprehensive biosafety evaluations further confirmed the excellent biocompatibility of CeCur NPs, underscoring their potential as a promising therapeutic strategy for accelerating diabetic wound healing.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: